Overview

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.

Phase:

N/A

Details

Lead Sponsor:

Hospital Authority, Hong Kong

Collaborator:

Baxter Healthcare Corporation

Treatments:

Androgens
Zoledronic Acid